医学
肺癌
药品
肿瘤科
癌症
内科学
肺
癌症研究
生物
药理学
作者
Misako Nagasaka,Danielle Brazel,Ignatius Sai-Hong Ou
标识
DOI:10.1080/13543784.2024.2305131
摘要
Introduction While crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC), unmet needs remain. These unmet needs include treatment options for patients with resistance mutations and efficacious options even in the presence of brain metastasis while simultaneously avoiding unwanted neurological side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI